Seeking Alpha
08 Aug 2026, 06:07 UTC · 14w ago
Precigen: Has To Grow Into Its Valuation
Impact · against what's priced in
Precigen is currently a one-product story with high margins, but its $2.24 billion valuation leaves little room for error. While the initial commercial success of PAPZIMEOS is strong, the weakness of the remaining pipeline suggests limited long-term catalysts to justify the current premium.
- PGEN+0.20
No priced-in read yet
- In context
The FDA approval and $53.1 million in Q2 revenue for PAPZIMEOS, paired with minimal COGS of $2.8 million, demonstrate strong immediate profitability, though this is balanced by a pipeline that lags behind competitors in efficacy.
Read from the article alone

Top 1 mover · tap to explore




